BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

Rhea-AI Summary

BridgeBio (Nasdaq: BBIO) will present additional interim Phase 3 FORTIFY data for BBP-418 in LGMD2I/R9 at the MDA Clinical & Scientific Conference in Orlando, March 8-11, 2026. A late-breaking oral presentation on March 11 will report the interim analysis meeting efficacy endpoints; collaborators will deliver one oral talk and four posters.

News Market Reaction – BBIO

+3.11%

1 alert

+3.11% News Effect

On the day this news was published, BBIO gained 3.11%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: March 8–11, 2026 Late-breaking presentation time: March 11, 2:00 pm ET Oral presentation time: March 11, 11:30 am ET +1 more

4 metrics

Conference dates March 8–11, 2026 MDA Clinical & Scientific Conference in Orlando

Late-breaking presentation time March 11, 2:00 pm ET Interim Phase 3 FORTIFY data for BBP‑418

Oral presentation time March 11, 11:30 am ET High-throughput assay for ribitol response across FKRP variants

Number of posters 4 posters LGMD2I/R9 disease burden, real-world insights, outcomes, and BBP‑418 journey

Market Reality Check

Price: $68.56 Vol: Volume 1,870,210 shares v...

low vol

$68.56 Last Close

Volume Volume 1,870,210 shares vs 20-day average 3,642,235 shares indicates lighter trading ahead of the data presentation. low

Technical Price $64.53 is trading above the $57.65 200-day moving average, reflecting a pre-existing upward trend.

Peers on Argus

BBIO was down 1.48% while high-affinity peers were mixed (e.g., BMRN -2.42%, ASN...

2 Up

BBIO was down 1.48% while high-affinity peers were mixed (e.g., BMRN -2.42%, ASND +1.39%). Momentum scanner flagged MRNA and ROIV moving up without news, suggesting today’s setup looks more stock-specific than a broad biotech move.

Previous Clinical trial Reports

5 past events · Latest: Feb 12 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 12	Phase 3 topline data	Positive	+3.7%	Reported positive Phase 3 PROPEL 3 topline results for oral infigratinib.
Oct 29	Phase 3 topline data	Positive	+3.3%	Announced positive Phase 3 CALIBRATE results for encaleret in ADH1.
Oct 27	Phase 3 topline data	Positive	+17.1%	Reported positive Phase 3 FORTIFY results for BBP‑418 in LGMD2I/R9.
Sep 06	Phase 2 proof-of-concept	Positive	+1.7%	Shared positive Phase 2 proof‑of‑concept data for encaleret in post‑surgical hypoparathyroidism.
Jun 12	Preclinical data publication	Positive	+1.5%	Highlighted Science publication of preclinical data for RAS:PI3Kα breaker BBO‑10203.

Pattern Detected

Clinical trial announcements have consistently been received positively, with all recent tagged events showing positive next-day price reactions.

Recent Company History

Over the past months, BridgeBio has repeatedly reported positive clinical data across multiple programs. Notably, the Phase 3 FORTIFY topline for BBP‑418 in LGMD2I/R9 on Oct 27, 2025 and Phase 3 wins for encaleret and infigratinib each led to gains between low- to high‑single digits, with one double‑digit move. This announcement, highlighting additional FORTIFY data at a major MDA conference, fits into that pattern of advancing late‑stage, genetically driven therapies.

Historical Comparison

+5.5% avg move · Clinical trial news for BBIO has historically produced average next-day moves of 5.48%, with consist...

clinical trial

+5.5%

Average Historical Move clinical trial

Clinical trial news for BBIO has historically produced average next-day moves of 5.48%, with consistently positive reactions across multiple late-stage readouts.

Across recent clinical trial updates, BridgeBio has progressed from Phase 2 proof-of-concept to multiple positive Phase 3 readouts, including FORTIFY for BBP‑418, encaleret in ADH1, and infigratinib in achondroplasia, reinforcing a pipeline transition toward registrational filings.

Market Pulse Summary

This announcement highlights additional Phase 3 FORTIFY data for BBP‑418 in LGMD2I/R9 to be presente...

Analysis

This announcement highlights additional Phase 3 FORTIFY data for BBP‑418 in LGMD2I/R9 to be presented as a late-breaking talk at a major MDA conference, alongside mechanistic and health‑economics work. In historical context, BridgeBio’s clinical updates have been consistently positive and have supported plans for multiple NDA submissions. Investors may focus on how these new data reinforce the prior FORTIFY topline and clarify the therapeutic and economic profile of BBP‑418 within LGMD2I/R9.

Key Terms

phase 3 clinical trial, limb-girdle muscular dystrophy type 2i/r9, lgmd2i/r9, late-breaking oral presentation, +3 more

7 terms

phase 3 clinical trial medical

"additional data from the interim analysis of FORTIFY, the Phase 3 clinical trial of BBP-418"

A phase 3 clinical trial is a large-scale study that tests a new medical treatment or drug to determine if it is safe and effective for widespread use. It often involves hundreds or thousands of participants and compares the new treatment to existing options or a placebo. For investors, the results of this phase are crucial, as successful outcomes can lead to regulatory approval and commercial success, while failures may halt development.

limb-girdle muscular dystrophy type 2i/r9 medical

"BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9)"

A genetic form of muscular dystrophy that mainly weakens the muscles around the hips and shoulders and can also affect the heart and breathing; it progresses over years and varies in severity from person to person. For investors, it matters because the clear genetic cause and measurable disease course make it a defined target for drug development, clinical trials, and potential therapies—similar to fixing a specific faulty part in a machine, which helps estimate market size, regulatory hurdles, and commercial opportunity.

lgmd2i/r9 medical

"BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9)"

LGMD2I/R9 is an inherited form of limb-girdle muscular dystrophy caused by mutations in a single gene that leads to progressive weakness of the muscles around the hips and shoulders. For investors, it defines a specific, well-characterized patient group and unmet medical need: therapies that slow or reverse this genetic defect can win clear regulatory paths, predictable clinical trial designs, and a concentrated market, much like fixing a single faulty blueprint that weakens a building.

late-breaking oral presentation technical

"will be shared in a late-breaking oral presentation at the MDA Clinical and Scientific Conference"

A late-breaking oral presentation is a spoken announcement at a scientific or medical conference that was added close to the meeting date to share newly available clinical, regulatory, or trial results. It matters to investors because it often delivers fresh, potentially market-moving data before it appears in journals, like a breaking-news broadcast that can quickly change expectations about a drug’s effectiveness, safety, or regulatory outlook and therefore affect a company’s stock.

high-throughput assay medical

"A High-Throughput Assay for Measuring Ribitol Response Across FKRP Variants"

A high-throughput assay is a laboratory method that tests large numbers of samples or compounds quickly and automatically, like a conveyor belt that evaluates thousands of items for a particular effect. For investors, it matters because faster, scaled testing can speed drug or diagnostic discovery, reduce development costs, and increase the chance of finding promising candidates—potentially shortening timelines to value-driving milestones such as partnerships, clinical trials, or product launch.

ribitol medical

"A High-Throughput Assay for Measuring Ribitol Response Across FKRP Variants"

Ribitol is a simple sugar alcohol that acts like a small biochemical building block found in some cells and laboratory reagents. Investors pay attention because ribitol can be an input in diagnostics, research tools, or drug-related manufacturing; changes in demand, supply or regulatory status can affect costs, production capacity and revenue prospects for companies that use or sell it. Think of it as a specialty raw material whose availability and price can influence biotech operations.

quality-adjusted life-years medical

"Long-Term Survival, Quality-Adjusted Life-Years, and Economic Burden in LGMD2I/R9"

Quality-adjusted life-years (QALYs) measure health impact by combining how long a treatment extends life with the quality of that life into a single number — one QALY equals one year in perfect health, while poorer health or shorter time count as fractions. Investors care because regulators and payers use QALYs to judge a treatment’s cost-effectiveness and decide pricing and reimbursement, so QALY-based assessments can materially affect a therapy’s market access and revenue potential, similar to a cost-per-mile measure for cars.

AI-generated analysis. Not financial advice.

PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data from the interim analysis of FORTIFY, the Phase 3 clinical trial of BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), will be shared in a late-breaking oral presentation at the MDA Clinical and Scientific Conference, taking place in Orlando, Florida on March 8-11, 2026. Additionally, an oral presentation from BridgeBio’s academic collaborators at Yale School of Medicine, along with four posters, will highlight advances in the understanding of BBP-418 and LGMD2I/R9.

Late-Breaking Oral Presentation:
Interim Analysis from Ongoing Phase 3 FORTIFY Study of BBP-418 for Patients with LGMD2I/R9 Meets Efficacy Endpoints
Presenter: Katherine Mathews, M.D., Professor of Pediatrics and Neurology at the University of Iowa’s Roy J. and Lucille A. Carver College of Medicine
Date: Wednesday, March 11 at 2:00 pm ET

Oral Presentation:
A High-Throughput Assay for Measuring Ribitol Response Across FKRP Variants
Presenter: Yujiao Yang, Ph.D., Postdoctoral Associate in the Laboratory of Monkol Lek at Yale School of Medicine
Date: Wednesday, March 11 at 11:30 am ET

Posters:
Systematic Literature Review of Clinical Outcomes and Disease Burden in LGMD2I/R9
Date: Tuesday, March 10

Real-World Insights into LGMD, Including Subtype 2I/R9: Treatment Patterns, Health Care Resource Utilization, and Costs
Date: Tuesday, March 10

Long-Term Survival, Quality-Adjusted Life-Years, and Economic Burden in LGMD2I/R9: A Health Outcomes Model
Date: Tuesday, March 10

The Journey of BBP-418: From LGMD2I/R9 Disease Pathophysiology to Registrational Clinical Trials
Date: Tuesday, March 10

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com  
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

FAQ

What will BridgeBio (BBIO) present at the MDA Conference March 8-11, 2026?

BridgeBio will present additional interim Phase 3 FORTIFY data for BBP-418, including a late-breaking oral session on March 11. According to BridgeBio, the interim analysis met efficacy endpoints, and collaborators will present one oral talk plus four posters highlighting BBP-418 and LGMD2I/R9 research.

When is the late-breaking oral presentation for BBP-418 (BBIO) at the MDA Conference?

The late-breaking oral presentation is scheduled for Wednesday, March 11 at 2:00 pm ET. According to BridgeBio, Katherine Mathews, M.D., will present interim FORTIFY results showing the ongoing study met efficacy endpoints during that session.

What other BridgeBio (BBIO) presentations are planned at the MDA Clinical & Scientific Conference?

An additional oral presentation and four posters will be presented, covering assays, real-world insights, and economic models. According to BridgeBio, Yale collaborators will present a high-throughput assay and four posters on clinical outcomes, resource use, economics, and BBP-418 development.

What did the interim FORTIFY analysis for BBP-418 indicate in the BridgeBio (BBIO) announcement?

The interim analysis from the ongoing Phase 3 FORTIFY study met efficacy endpoints, per the company. According to BridgeBio, those positive interim findings will be discussed in the late-breaking oral presentation on March 11, 2026 at the MDA Conference.

Who will present the FORTIFY interim results for BBP-418 (BBIO) at the MDA Conference?

Katherine Mathews, M.D., Professor of Pediatrics and Neurology, will present the late-breaking interim FORTIFY analysis. According to BridgeBio, Dr. Mathews will speak on Wednesday, March 11 at 2:00 pm ET about the efficacy endpoints met.